JP2021505655A - ウィルソン病を治療するためのビスコリンテトラチオモリブデート - Google Patents

ウィルソン病を治療するためのビスコリンテトラチオモリブデート Download PDF

Info

Publication number
JP2021505655A
JP2021505655A JP2020547315A JP2020547315A JP2021505655A JP 2021505655 A JP2021505655 A JP 2021505655A JP 2020547315 A JP2020547315 A JP 2020547315A JP 2020547315 A JP2020547315 A JP 2020547315A JP 2021505655 A JP2021505655 A JP 2021505655A
Authority
JP
Japan
Prior art keywords
tetrathiomolybdate
dose
patient
bischolin
bischoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020547315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505655A5 (enExample
Inventor
カール・ビャートマー
カール−ハインツ・ヴァイス
マイケル・シルスキー
フレドリック・アスカリ
アンナ・シャロンクォスカ
ペーター・フェレンチ
ペーター・ヘデラ
アフタブ・アラ
Original Assignee
アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー filed Critical アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー
Publication of JP2021505655A publication Critical patent/JP2021505655A/ja
Publication of JP2021505655A5 publication Critical patent/JP2021505655A5/ja
Priority to JP2023038205A priority Critical patent/JP2023075247A/ja
Priority to JP2025010250A priority patent/JP2025066802A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020547315A 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート Pending JP2021505655A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023038205A JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US62/594,184 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US62/646,553 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US62/655,568 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US62/669,095 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US62/741,313 2018-10-04
US201862750595P 2018-10-25 2018-10-25
US62/750,595 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023038205A Division JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Publications (2)

Publication Number Publication Date
JP2021505655A true JP2021505655A (ja) 2021-02-18
JP2021505655A5 JP2021505655A5 (enExample) 2022-01-11

Family

ID=64661349

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020547315A Pending JP2021505655A (ja) 2017-12-04 2018-12-04 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023038205A Pending JP2023075247A (ja) 2017-12-04 2023-03-13 ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2025010250A Pending JP2025066802A (ja) 2017-12-04 2025-01-24 ウィルソン病を治療するためのビスコリンテトラチオモリブデート

Country Status (17)

Country Link
US (3) US11510944B2 (enExample)
EP (3) EP4029498B1 (enExample)
JP (3) JP2021505655A (enExample)
KR (1) KR102803161B1 (enExample)
AU (1) AU2018379255B2 (enExample)
BR (1) BR112020011055A2 (enExample)
CA (1) CA3084100A1 (enExample)
DK (2) DK4029498T3 (enExample)
ES (2) ES3026756T3 (enExample)
FI (1) FI4029498T3 (enExample)
HU (2) HUE058921T2 (enExample)
IL (1) IL275115B2 (enExample)
MX (1) MX2020006284A (enExample)
PL (2) PL4029498T3 (enExample)
PT (2) PT4029498T (enExample)
SI (2) SI3720433T1 (enExample)
WO (1) WO2019110619A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549814A (ja) * 2020-11-13 2023-11-29 アレクシオン ファーマシューティカルズ， インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018379255B2 (en) * 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate
US20220387370A1 (en) 2019-11-21 2022-12-08 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
US20240044920A1 (en) * 2020-09-11 2024-02-08 Alexion Pharmaceuticals, Inc. Anti-ceruloplasmin antibodies and uses thereof
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
JP2024532131A (ja) * 2021-08-17 2024-09-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法
WO2024162974A1 (en) 2023-01-30 2024-08-08 Alexion Pharmaceuticals, Inc. Tetrathiomolybdic acid for use in treating copper metabolism-associated diseases or disorders (wilson disease)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538093A (ja) * 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
JP2006506466A (ja) * 2002-07-23 2006-02-23 アテニュオン，リミティド ライアビリティー カンパニー チオモリブデン酸類似物及びそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084818A2 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
AU2018379255B2 (en) 2017-12-04 2024-10-17 Alexion Pharma International Operations Unlimited Company Bis-choline tetrathiomolybdate for treating Wilson Disease
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
WO2019154876A1 (en) 2018-02-06 2019-08-15 Wilson Therapeutics Ab Crystalline particles of bis-choline tetrathiomolybdate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538093A (ja) * 2002-07-23 2005-12-15 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 抗血管形成療法のための、テトラポリアンモニウムテトラチオモリブデートおよび関連化合物
JP2006506466A (ja) * 2002-07-23 2006-02-23 アテニュオン，リミティド ライアビリティー カンパニー チオモリブデン酸類似物及びそれらの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEPATOLOGY, vol. Vol.66, No.1(Suppl), JPN6022051667, October 2017 (2017-10-01), pages 429 - 802, ISSN: 0005219519 *
JOURNAL OF HEPATOLOGY, vol. 66, JPN6022051666, April 2017 (2017-04-01), pages 88 - 016, ISSN: 0005219518 *
LANCET GASTROENTEROL HEPATOL, vol. 2, JPN6022051664, 5 October 2017 (2017-10-05), pages 869 - 876, ISSN: 0005219516 *
MOVEMENT DISORDERS, vol. Vol.32, Suppl.2, JPN6022051665, June 2017 (2017-06-01), pages 455 - 1184, ISSN: 0005219517 *
岡山医学会雑誌, vol. 127, JPN6023023921, 2015, pages 245 - 249, ISSN: 0005219520 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549814A (ja) * 2020-11-13 2023-11-29 アレクシオン ファーマシューティカルズ， インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法

Also Published As

Publication number Publication date
MX2020006284A (es) 2021-04-12
US20230070534A1 (en) 2023-03-09
EP4523745A3 (en) 2025-05-14
WO2019110619A1 (en) 2019-06-13
KR102803161B1 (ko) 2025-05-07
DK4029498T3 (da) 2025-04-28
EP3720433A1 (en) 2020-10-14
SI3720433T1 (sl) 2022-09-30
PT3720433T (pt) 2022-05-03
IL275115B2 (en) 2025-10-01
KR20200096798A (ko) 2020-08-13
ES2912306T3 (es) 2022-05-25
US20210137972A1 (en) 2021-05-13
DK3720433T3 (da) 2022-05-02
PL4029498T3 (pl) 2025-06-02
US11510944B2 (en) 2022-11-29
AU2018379255B2 (en) 2024-10-17
PL3720433T3 (pl) 2022-07-18
FI4029498T3 (fi) 2025-04-29
EP4523745A2 (en) 2025-03-19
HUE071155T2 (hu) 2025-08-28
IL275115A (en) 2020-07-30
JP2025066802A (ja) 2025-04-23
ES3026756T3 (en) 2025-06-12
PT4029498T (pt) 2025-05-06
RU2020122023A (ru) 2022-01-10
EP4029498A1 (en) 2022-07-20
AU2018379255A1 (en) 2020-06-25
SI4029498T1 (sl) 2025-07-31
CA3084100A1 (en) 2019-06-13
IL275115B1 (en) 2025-06-01
US20210177894A1 (en) 2021-06-17
JP2023075247A (ja) 2023-05-30
BR112020011055A2 (pt) 2020-11-17
US12233088B2 (en) 2025-02-25
EP3720433B1 (en) 2022-02-02
EP4029498B1 (en) 2025-02-05
HUE058921T2 (hu) 2022-09-28

Similar Documents

Publication Publication Date Title
US12233088B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
JP2024180450A (ja) ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
US20220152057A1 (en) Methods and compositions for treating various disorders
US11419832B2 (en) Bis-choline tetrathiomolybdate for treating Wilson Disease
JP2008513491A (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
US20200113883A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
JP2009515952A (ja) 制御放出性製剤のクエチアピン
US20250082674A1 (en) Methods of treating copper metabolism-associated diseases or disorders
US20160128954A1 (en) Methods of Treating Huntington's Disease Using Cysteamine Compositions
AU2020358156B2 (en) Method for treating HIV with cabotegravir and rilpivirine
AU2013221604B2 (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
RU2787632C2 (ru) Бис-холина тетратиомолибдат для лечения болезни вильсона
WO2023038909A1 (en) Methods of treating copper metabolism-associated diseases or disorders
US20220071938A1 (en) Treatment of hyperammonemia in patients with renal insufficiency
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
HK40081935A (en) Treatment of amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231127

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117